- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Germany Tops Quality-Ranking Categories in CPhI Global Pharma Index
The CPhI Global Pharma Index, launched at this year's CPhI Worldwide event organized by UBM, is the world’s first ever reputation league table of major pharma industries, scoring the reputations of the major pharma economies across a range of attributes. Germany finished top of the rankings for pharmaceutical quality in both APIs and finished dosage drugs. Germany was also voted by the industry as the best country for both knowledge of its pharma professionals and transparency index – essentially, a rank of countries with the best regulations, business transparency and anti-corruption practices. Highlighting the industry’s confidence, of the 500 pharma companies surveyed in the CPhI Global Pharma Index, nearly 80% of respondents were either ‘confident’ or ‘extremely confident’ (60%) in their business outlook for 2018, and 84% of companies stated they are actively looking for new international partners.
This year's CPhI Worldwide closed its 28th edition with pre-audit figures indicating a record-breaking attendance of over 44,500* and 2,598 exhibitors. Held in Frankfurt, Germany, the world’s largest pharma event saw attendees from 169 countries – 25% of which are CEO or board level.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
